ASH2019 – Regeneron takes the bispecific baton and runs

ASH2019 – Regeneron takes the bispecific baton and runs

Source: 
EP Vantage
snippet: 

Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.